Clinical Trials Logo

Intellectual Disability clinical trials

View clinical trials related to Intellectual Disability.

Filter by:

NCT ID: NCT00298818 Completed - Epilepsy Clinical Trials

Open Label Study of Zonisamide in the Treatment of Epilepsy in Patients With Mental Retardation

Start date: August 2002
Phase: Phase 4
Study type: Observational

The purpose of this study is to assess the efficacy and tolerability in "real-world" clinical practice, of adjunctive zonisamide treatment in adult patients with developmental disabilities and epilepsy.

NCT ID: NCT00282191 Completed - Spasticity Clinical Trials

Prevalence of Spasticity in Adults With Mental Retardation Living in the Community

Start date: August 2006
Phase: Phase 1
Study type: Observational

This survey aims to investigate the prevalence of spasticity among adults who live in community settings in Davidson County, Tennessee. The treatment of spasticity in those who live in community homes could significantly increase a person's quality of life by allowing them to participate more independently in activities of daily living, or by making assistance easier for caregivers.

NCT ID: NCT00207935 Completed - Epilepsy Clinical Trials

Use of Sustained Release Antiepileptic Medication (Depakote® ER) for Pediatric Epilepsy in a Mental Retardation/Developmental Disorder Population

Start date: August 2005
Phase: Phase 4
Study type: Interventional

This study is being done to see if children with learning problems can learn how to swallow pills without chewing them. The reason this is important is that if a person has seizures, medications must be taken every day. Most medications need to be taken 2 or 3 times per day. Some medications have slow release and only are taaken once per day. Medications with slow release usually come in capsule form and cannot be opened or chewed. This study investiates whether children with developmental delay can be taught how to swalow pills.

NCT ID: NCT00190411 Completed - Clinical trials for EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT

Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type

Start date: October 2003
Phase: Phase 4
Study type: Interventional

Ehlers-Danlos syndrome vascular type (EDS-IV) is caused by a genetic defect of collagen type III. Patient die (median 40 yrs) of vascular complications. There is no treatment. We showed that arteries are thin and overloaded in this patients. We test the protective effect of celiprolol on cardiovascular events in a 5 years, randomized, PROBE design

NCT ID: NCT00156221 Completed - Autism Clinical Trials

MR Scanning of Very Young Children With Severe Developmental Disorders

Start date: September 2000
Phase: N/A
Study type: Observational

The specific is to study the MR morphologic and spectroscopic brain correlates and predictors of development in children with severe developmental disorders (autistic spectrum disorders and/or mental retardation and/or language disorders). Given the frequently observed association of autism with known medical conditions, particularly in cases with comorbid mental retardation and in cases with atypical autism (Rutter et al., 1994; Gillberg, 1995), children with suspected autism or related developmental disorders will be asked to participate in an extensive state of the art laboratory work-up which includes T1 and T2 weighted MRI of the brain. MRI data will be analyzed both qualitatively, looking for focal abnormalities and degree of myelination, and quantitatively, measuring volumes of total brain, cerebellum, ventricles and grey and white matter. For research purposes, the work-up will be supplied with proton Magnetic Resonance Spectroscopy (MRS) of the brain. This data set provides the opportunity to chart brain-behavior relationships in young children with suspected autism and related PDD cross-sectionally.

NCT ID: NCT00065936 Active, not recruiting - Mental Retardation Clinical Trials

Self-Injury: Diagnosis and Treatment

Start date: July 1997
Phase: Phase 3
Study type: Interventional

Self-injurious behavior is behavior in which a person hurts or harms himself. This behavior sometimes occurs in people with mental retardation or autism. This study will evaluate self-injurious behavior in people with mental retardation or autism and will test the effectiveness of new treatments.

NCT ID: NCT00065286 Completed - Akathisia Clinical Trials

Akathisia (Restless Legs Syndrome) in People With Schizophrenia and Mental Retardation

Start date: December 1996
Phase: Phase 3
Study type: Observational

Akathisia is a movement disorder that is often a side effect of certain psychiatric drugs. People with akathisia are unable to sit or keep still, complain of restlessness, fidget, rock from foot to foot, and pace. Akathisia is sometimes called “restless legs syndrome.” The drugs that can cause akathisia are most often used to treat patients with schizophrenia or mental retardation (MR). This study will evaluate akathisia in both schizophrenic and MR patients who either have long-term akathisia or who are starting treatment with psychiatric drugs.

NCT ID: NCT00065273 Completed - Mental Retardation Clinical Trials

Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay

Start date: July 1998
Phase: Phase 3
Study type: Interventional

Psychiatric drugs are often used to treat behavioral symptoms of mental retardation/developmental delay (MR/DD). These drugs can cause serious side effects. Newer drugs may have decreased side effects. This study will compare new and old drugs used to treat behavioral symptoms in people with MR/DD.

NCT ID: NCT00004300 Suspended - Mental Retardation Clinical Trials

Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis

Start date: n/a
Phase: Phase 2
Study type: Interventional

OBJECTIVES: I. Determine differences between persons with repetitive behavior disorders and matched controls on measures of motor control relevant to basal ganglia pathophysiology. II. Determine the efficacy of bromocriptine, a dopamine agonist, in the treatment of stereotyped behavior and related behavior disorders. III. Determine the efficacy of sertraline hydrochloride, a selective serotonin uptake inhibitor, in the treatment of repetitive behavior disorders. IV. Identify behavioral, environmental, and biological variables with differential drug treatment response.

NCT ID: NCT00001639 Completed - Mental Retardation Clinical Trials

Evaluation of Patients With Unresolved Chromosome Abnormalities

Start date: December 1996
Phase: N/A
Study type: Observational

The purpose of this research is to study a new way to test for chromosome abnormalities. Chromosomes are strands of DNA (the genetic material in the cell nucleus) that are made up of genes-the units of heredity. Chromosome abnormalities are usually investigated by staining the chromosomes with a dye (Giemsa stain) and examining them under a microscope. This method can detect many duplications and deletions of pieces of chromosomes and is very accurate in diagnosing certain abnormalities. It is not useful, however, for identifying very small abnormalities. This study will evaluate the accuracy of a test method using 24 different dyes for finding small chromosome abnormalities. Children and adults with various chromosome abnormalities may be eligible for this study, including, for example, people with developmental delay or mental retardation, abnormal growth features or growth retardation, and certain behavioral disorders. Participants will be evaluated in the clinic over a 1- to 3-day period, depending on their symptoms. All participants will be examined by a genetics specialist and will have a physical examination and possibly X-rays, computerized tomography (CT) scans, magnetic resonance imaging (MRI), ultrasound studies and medical photography. Blood will be drawn for chromosome testing-about 3 tablespoons from adults and 1 to 3 teaspoons from children. When the test results are available, participants will return to the clinic for follow-up evaluation and review of the test findings. The genetic and medical evaluations, along with their implications, will be discussed.